Skip to contentG
Gilead Sciences, Inc.
G
GILDGilead Sciences, Inc. Q1 2026 · 10-Q
Revenue$6.96B$6.96B+4.4% vs Q1 2025 Net Income$2.02B$2.02B+53.7% vs Q1 2025 EPS Diluted$1.61$1.61+54.8% vs Q1 2025 Operating Income$2,586,000,000+15.6% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Gilead Sciences, Inc. · CIK 882095 · Engraved from SEC EDGAR
Free Cash Flowderived$2,427,000,000+46.8% Margins · derivedOperating margin37.2%+3.6 pt vs Q1 2025
Net margin29.0%+9.3 pt vs Q1 2025
ended Mar 31, 2026 · filed May 7, 2026 · 37 d after period end